2021 DORIS definition of remission in SLE: Final recommendations from an international task force

Ronald F. van Vollenhoven, George Bertsias, Andrea Doria, David Isenberg, Eric Morand, Michelle A. Petri, Bernardo A. Pons-Estel, Anisur Rahman, Manuel Francisco Ugarte-Gil, Alexandre Voskuyl, Laurent Arnaud, Ian N. Bruce, Ricard Cervera, Nathalie Costedoat-Chalumeau, Caroline Gordon, Frédéric A. Houssiau, Marta Mosca, Matthias Schneider, Michael M. Ward, Graciela AlarconMartin Aringer, Anka Askenase, Sang Cheol Bae, Hendrika Bootsma, Dimitrios T. Boumpas, Hermine Brunner, Ann Elaine Clarke, Cindy Coney, László Czirják, Thomas Dörner, Raquel Faria, Rebecca Fischer, Ruth Fritsch-Stork, Murat Inanc, Søren Jacobsen, David Jayne, Annegret Kuhn, Bernadette van Leeuw, Maarten Limper, Xavier Mariette, Sandra Navarra, Mandana Nikpour, Marzena Helena Olesinska, Guillermo Pons-Estel, Juanita Romero-Diaz, Blanca Rubio, Yehuda Schoenfeld, Eloisa Bonfá, Josef Smolen, Y. K.Onno Teng, Angela Tincani, Michel Tsang-A-Sjoe, Carlos Vasconcelos, Anne Voss, Victoria P. Werth, Elena Zakharhova, Cynthia Aranow

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

Original languageEnglish
Article numbere000538
JournalLupus Science and Medicine
Volume8
Issue number1
DOIs
StatePublished - 24 Nov 2021

Fingerprint

Dive into the research topics of '2021 DORIS definition of remission in SLE: Final recommendations from an international task force'. Together they form a unique fingerprint.

Cite this